IL1B and Alzheimer disease: After four weeks of WT administration to AD-fed ApoE−/− mice, decreased TNF-α, interleukin (IL)-1β, IL-6, IL-12, and ADAM10 and ADAM17 enzyme activities were observed (p < 0.05).